Compare EPRT & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPRT | PTCT |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.3B |
| IPO Year | 2018 | 2013 |
| Metric | EPRT | PTCT |
|---|---|---|
| Price | $31.17 | $78.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | $35.50 | ★ $73.76 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ 8.17 | N/A |
| EPS | 1.24 | ★ 8.94 |
| Revenue | $531,061,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $23.36 | $119.02 |
| Revenue Next Year | $17.23 | N/A |
| P/E Ratio | $25.05 | ★ $8.78 |
| Revenue Growth | 23.93 | ★ 97.54 |
| 52 Week Low | $27.44 | $35.95 |
| 52 Week High | $34.01 | $87.50 |
| Indicator | EPRT | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 54.13 | 58.39 |
| Support Level | $31.35 | $75.34 |
| Resistance Level | $32.18 | $87.50 |
| Average True Range (ATR) | 0.47 | 3.01 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 45.14 | 37.82 |
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.